Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$227.62 USD
+9.38 (4.30%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $222.99 -4.63 (-2.03%) 4:46 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRL 227.62 +9.38(4.30%)
Will CRL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRL
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
Charles River (CRL) Inks CDMO Deal With Gates Institutes
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
Other News for CRL
Charles River removed from 'Tactical Outperform' list at Evercore ISI
ClearBridge Select Strategy Q2 2024 Commentary
Aristotle Capital Small/Mid Cap Equity Q2 2024 Commentary
Creightons PLC Reports Resilient Financial Performance
GET READY: AJ Bell, Anglo American, Dunelm and SSE at 0700 BST